Literature DB >> 20135723

Pericardiocentesis with cisplatin for malignant pericardial effusion and tamponade.

Takatsugu Oida1, Kenji Mimatsu, Hiso Kano, Atsushi Kawasaki, Youichi Kuboi, Nobutada Fukino, Sadao Amano.   

Abstract

AIM: To evaluate the role and outcome of pericardiocentesis with intrapericardial cisplatin instillation for malignant pericardial effusion resulting from esophageal cancer.
METHODS: We retrospectively studied 7 patients who underwent pericardiocentesis with intrapericardial cisplatin instillation for malignant pericardial effusion resulting from esophageal cancer. After pericardiocentesis, we performed catheterization of the pericardial space under ultrasonogram guidance. Malignant etiology of the pericardial fluid was confirmed by cytological examination. Subsequently, cisplatin (10 mg in 20 mL normal saline) was instilled into the pericardial space.
RESULTS: The mean total volume of the aspirated effusion fluid was 782 +/- 264 mL (range, 400-1200 mL). The drainage catheter was successfully removed in all patients, and the mean duration of pericardial drainage was 7.7 +/- 2.7 d (range, 5-13 d). No fluid reaccumulation was observed. Mean survival time was 120 +/- 71 d (range, 68-268 d).
CONCLUSION: Pericardiocentesis along with catheter drainage appears to be a safe and effective for pericardial malignant effusion and tamponade, and cisplatin instillation prevents recurrence.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20135723      PMCID: PMC2817063          DOI: 10.3748/wjg.v16.i6.740

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  21 in total

Review 1.  Practical aspects of the management of pericardial disease.

Authors:  Bernhard Maisch; Arsen D Ristić
Journal:  Heart       Date:  2003-09       Impact factor: 5.994

2.  Guidelines on the diagnosis and management of pericardial diseases executive summary; The Task force on the diagnosis and management of pericardial diseases of the European society of cardiology.

Authors:  Bernhard Maisch; Petar M Seferović; Arsen D Ristić; Raimund Erbel; Reiner Rienmüller; Yehuda Adler; Witold Z Tomkowski; Gaetano Thiene; Magdi H Yacoub
Journal:  Eur Heart J       Date:  2004-04       Impact factor: 29.983

3.  Cardiac tamponade: an unusual, lifethreatening complication after transhiatal resection of the esophagus.

Authors:  Suzanne Kats; Grard A P Nieuwenhuijzen; Bart H M van Straten; Jacques P A M Schönberger
Journal:  Interact Cardiovasc Thorac Surg       Date:  2006-12-05

4.  Pleural pericardial window for palliation of cardiac tamponade due to cancer.

Authors:  G J Hill; B I Cohen
Journal:  Cancer       Date:  1970-07       Impact factor: 6.860

5.  Intrapericardial tetracycline for the management of cardiac tamponade secondary to malignant pericardial effusion.

Authors:  S Davis; S M Sharma; E D Blumberg; C S Kim
Journal:  N Engl J Med       Date:  1978-11-16       Impact factor: 91.245

6.  Cardiomediastinal tamponade and shock following three-stage transthoracic oesophagectomy.

Authors:  V Cherian; J V Divatia; A Kulkarni; D Dasgupta
Journal:  J Postgrad Med       Date:  2001 Jul-Sep       Impact factor: 1.476

7.  Radiation therapy of cardiac and pericardial metastases.

Authors:  W C Cham; A H Freiman; P H Carstens; F C Chu
Journal:  Radiology       Date:  1975-03       Impact factor: 11.105

8.  Neoplastic pericardial effusion. Efficacy and safety of intrapericardial treatment with cisplatin.

Authors:  B Maisch; A D Ristić; S Pankuweit; A Neubauer; R Moll
Journal:  Eur Heart J       Date:  2002-10       Impact factor: 29.983

9.  Cardiac tamponade and pulmonary compression due to volvulus of oesophageal coloplasty.

Authors:  J L Canivet; S Piret; G Hick; P Damas
Journal:  Acta Anaesthesiol Belg       Date:  2004

10.  The treatment of malignant pericardial effusion in carcinoma of the breast.

Authors:  P M Reynolds; M J Byrne
Journal:  Aust N Z J Med       Date:  1977-04
View more
  7 in total

1.  Constrictive pericarditis caused by a pericardial-occupying tumor due to esophageal cancer.

Authors:  Saeko Kushida; Naoki Takekawa; Takuya Mimura; Hidetaka Tsumura; Takeshi Sakamoto; Kazutoshi Tobimatsu; Ikuya Miki; Yoshinobu Yamamoto; Masahiro Tsuda; Hideto Inokuchi
Journal:  Clin J Gastroenterol       Date:  2014-04-23

2.  Neoplastic pericardial disease: Old and current strategies for diagnosis and management.

Authors:  Chiara Lestuzzi
Journal:  World J Cardiol       Date:  2010-09-26

3.  Constrictive pericarditis caused by pericardial metastasis from esophageal squamous cell carcinoma: a case report.

Authors:  Takayoshi Kishino; Kensuke Kumamoto; Hiroyuki Matsukawa; Akihiro Kondo; Yasuhisa Ando; Jun Uemura; Hironobu Suto; Eisuke Asano; Minoru Oshima; Yoichi Chiba; Masaki Ueno; Sayako Nakagawa; Shohei Kitamoto; Yoichi Yamashita; Taiko Horii; Keiichi Okano
Journal:  Int Cancer Conf J       Date:  2022-03-15

4.  Better efficacy of intrapleural infusion of bevacizumab with pemetrexed for malignant pleural effusion mediated from nonsquamous non-small cell lung cancer.

Authors:  Xinyu Song; Dawei Chen; Jun Guo; Li Kong; Haiyong Wang; Zhehai Wang
Journal:  Onco Targets Ther       Date:  2018-11-27       Impact factor: 4.147

5.  Large Pericardial Effusion-Diagnostic and Therapeutic Options, with a Special Attention to the Role of Prolonged Pericardial Fluid Drainage.

Authors:  Małgorzata Dybowska; Monika Szturmowicz; Katarzyna Błasińska; Juliusz Gątarek; Ewa Augustynowicz-Kopeć; Renata Langfort; Paweł Kuca; Witold Tomkowski
Journal:  Diagnostics (Basel)       Date:  2022-06-13

6.  Sustained response of malignant pericardial effusion to intrapericardial bevacizumab in an advanced lung cancer patient: a case report and literature review.

Authors:  Dawei Chen; Yan Zhang; Fang Shi; Minghuan Li; Hui Zhu; Li Kong; Jinming Yu
Journal:  Onco Targets Ther       Date:  2015-10-01       Impact factor: 4.147

7.  Intrapericardial bevacizumab safely and effectively treats malignant pericardial effusion in advanced cancer patients.

Authors:  Dawei Chen; Yan Zhang; Fang Shi; Hui Zhu; Minghuan Li; Judong Luo; Kaijun Chen; Li Kong; Jinming Yu
Journal:  Oncotarget       Date:  2016-08-09
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.